新たに発症した1型糖尿病を逆転させるための,Granzyme B-Cleavable T細胞標的バイスペシフィック・セル・ベシクル・コネクター
Yanfang Wang1, Yanping Sun1, Xiuwen Zhang1
1State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Journal of the American Chemical Society
|January 27, 2025
まとめ
新しい細胞膀治療は,免疫機能を維持しながらCD8+ T細胞を標的として,新発症型の1型糖尿病 (T1D) を逆転させます. このアプローチは感染リスクを高めることなく,T1D治療の有望で安全な代替手段です.
科学分野:
- 免疫学
- 内分泌学
- バイオテクノロジー
背景:
- 1型糖尿病 (T1D) は,CD8+T細胞による臓β細胞の破壊によって特徴づけられる自己免疫疾患である.
- CD3抗体のような現在の治療は 初期段階では有効ですが 免疫抑制を一時的に引き起こし 感染リスクを高めます
- 免疫系を損なわずに病気の進行を逆転させる治療法が必要である.
研究 の 目的:
- 1型糖尿病の新規発症を逆転させるための新しい細胞膀ベースの治療法 (aCD8-GrzBcs-IL2) を開発し,評価する.
- 病原性CD8+T細胞を同時に抑制し,調節性T細胞 (Treg) を促進する治療法を設計する.
- 新薬の安全性と有効性を臨床前モデルで評価する.
主な方法:
- 抗CD8 scFvとIL-2ミューテインを含む,グラン酵素B反応性融合タンパク質 (aCD8-GrzBcs- IL2) を有する人工細胞小胞.
- CD8+ T細胞の細胞毒性を抑制し,Tレグ細胞の膨張を促進する細胞胞子の能力のインビトロ評価.
- aCD8- GrzBcs- IL2の静脈内投与は,肥満でない糖尿病 (NOD) のマウスで,新たに発症した糖尿病である.
主要な成果:
- 細胞小胞はCD8+ T細胞の殺戮を阻害し,Tレグ細胞の膨張を促した.
- aCD8- GrzBcs- IL2の静脈内投与は,NODマウスの77. 8%で新規発症した糖尿病を逆転させた.
- 治療はCD3+またはCD8+T細胞集団を全体的に減少させず,好ましい安全性プロファイルを示唆した.
結論:
- エンジニアリングされた細胞膀 (aCD8-GrzBcs-IL2) は,タイプ1糖尿病の二重作用の治療薬として潜在性を示しています.
- この治療は,免疫細胞集団を保存した臨床前モデルにおいて,新規発症の糖尿病を効果的に逆転させる.
- このアプローチはT1D治療の有望な戦略であり,既存の治療法と比較して安全性が向上しています.
関連する概念動画
Cytotoxic T Cells-mediated Immune Response
835
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
835
Glucagon-like Receptor Agonists
294
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K


